A. Desai

Publications13
h-index8
Citations140
Highly Influential Citations8
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • W. London
  • 328 Publications, 16,310 Citations
  • K. Matthay
  • 420 Publications, 25,188 Citations
  • J. Maris
  • 638 Publications, 29,818 Citations
  • R. Seeger
  • 330 Publications, 26,465 Citations
  • Publications
  • Influence
An anthropometric analysis of facial height, arch length, and palatal rugae in the Indian and Nepalese population
Introduction: A country such as India abounds with diverse population groups with distinct anthropometric characteristics. Among these, numerous Nepalese population groups are present in different… Expand
  • 28
  • 4
Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma
The optimal autologous stem cell rescue (HDC-SCR) regimen for children with high-risk neuroblastoma (HR-NBL) is not defined. Carboplatin/etoposide/melphalan (CEM) is the current US standard; however,… Expand
  • 19
  • 1
Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
PurposeCh14.18 improves survival in children with high-risk neuroblastoma but is associated with substantial toxicity. Ch14.18 pharmacokinetics were previously reported to be highly variable and… Expand
  • 25
  • 1
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy
AbstractPurposeDinutuximab (Unituxin™; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma. United… Expand
  • 13
  • 1
Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma
Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy… Expand
  • 8
  • 1
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients
Atypical chronic myeloid leukemia, BCR‐ABL1‐negative, (aCML) is a rare myeloid neoplasm. Recent adult data suggest the leukemic cells in a subset of patients are dependent on JAK/STAT signaling and… Expand
  • 15
The Evolution of Risk Classification for Neuroblastoma
Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are risk-stratified using a number of features including age at diagnosis, disease stage, tumor histology, MYCN… Expand
  • 10
  • PDF
Establishing a high‐risk neuroblastoma cohort using the pediatric health information system database
International Classification of Diseases, 9th Revision (ICD‐9) code(s) for neuroblastoma do not exist, preventing identification of these patients in administrative databases. To overcome this… Expand
  • 12
  • PDF
Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High‐Risk Neuroblastoma Using a National Administrative Database
High‐dose chemotherapy with autologous stem cell rescue (ASCR) is a key component of high‐risk neuroblastoma therapy. Resources required to support patients treated with ASCR conditioning regimens… Expand
  • 6
Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.
10069 Background: Cooperative group trials have improved outcomes for children with HR NBL. Trial data provide reliable information regarding patient characteristics, treatment, and response but do… Expand
  • 2